Metformin + Dapagliflozin Tablets bulk supplier for pharma manufacturers

Metformin + Dapagliflozin Tablets Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: (dapagliflozin/metformin): 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, 10 mg/1000 mg

Reference Brands: Xigduo XR®(US and EU)

Category: Diabetes

Metformin + Dapagliflozin Tablets is available in Tablets and strengths such as (dapagliflozin/metformin): 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, 10 mg/1000 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Metformin + Dapagliflozin Tablets is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Metformin + Dapagliflozin Tablets can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Product Description: In the US, dapagliflozin/metformin (Xigduo XR) was approved by the FDA in February 2014 for type 2 diabetes as an adjunct to diet and exercise, with a warning to stop temporarily before surgery to reduce ketoacidosis risk. In the EU, Xigduo received marketing authorization in January 2014, and Ebymect in November 2015, for glycemic control in adults when metformin alone is inadequate. The EMA expanded metformin use in 2016 to patients with moderate kidney impairment (GFR 30–59 ml/min), with dose adjustments and monitoring for lactic acidosis. For sourcing, check Pharmatradz.com for supplier details and availability

Frequently Asked Questions

Yes, Metformin + Dapagliflozin Tablets is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Metformin + Dapagliflozin Tablets is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Premixed Insulins (70/30, 50/50) Injectable

Strength:
U-100

Form: Vials, pens

Reference Brands: Humulin, Novolin(US); Mixtard, Humulin, Insuman(EU)

View Details
Insulin Lispro (Humalog) Injectable

Strength:
U-100, U-200

Form: Vials/pens

Reference Brands: Humalog, Admelog, Fiasp(US); Humalog, Fiasp(EU)

View Details
Insulin Aspart (Novolog) Injectable

Strength:
U-100, U-200

Form: Vials/pens

Reference Brands: Novolog, Fiasp(US &EU)

View Details
Insulin Glargine (Lantus) Injectable

Strength:
U-100, U-300

Form: Vials/pens

Reference Brands: Lantus, Basaglar, Toujeo(US); Lantus, Toujeo(EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.